Thu08222019

Last update04:30:33 PM

Back You are here: Home Biology & biomedicine

Peptides effective for inhibiting cholesterol aggregation in the vascular wall

A work demonstrates that peptides derived from a LRP1 receptor sequence are very effective inhibiting the aggregation of LDL (low density lipoprotein, also called 'bad' cholesterol) that takes place in the vascular wall during development of atherosclerosis.

Only the introduction is translated

Read more...

Low cost and reusable wearable sensors

Scientists at the CSIC have developed new portable and non-invasive sensors for monitoring biomarkers such as glucose, lactate or alcohol. They are based on wireless electro chromic and electrochemical sensors, and they can be used to detect metabolites in biological fluids, either human fluids (sweat, urine…) or in fluids derived from food products (e.g., leaking).

Read more...

A metabolite from a drug against diabetes, a possible treatment for neurodegenerative diseases

MIN-102, a metabolite from a drug against diabetes, could be useful for treating some neurodegenerative diseases, as scientists think. To confirm this hypothesis, a project has been launched with the involvement of the CSIC’s Instituto de Investigaciones Biomédicas de Barcelona, the Hospital Universitari 'Sant Joan de Déu' and the University of Lleida. The research project is led by the company Mynorix Therapeutics.

Read more...

Modulating compounds of KChIP2 and its use for the treatment of cardiovascular pathologies

CSIC and UAM have developed compounds that positively modulate protein-protein interactions that involve KChIP2protein. Industrial partners from the pharmaceutical industry are being sought to collaborate through a patent licence agreement.

Read more...

Preclinical trial with efavirenz for the treatment of Niemann-Pick C disease

A team of scientists from the Centro de Biología Molecular Severo Ochoa (CMBSO-CSIC) has developed a new treatment for the Niemann-Pick disease type C (NPC) based on the drug efavirenz. The study is at the preclinical stage.

Read more...